Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBER’s New Director 'Marks' New Era For Biologics Regulation

This article was originally published in The Pink Sheet Daily

Executive Summary

Peter Marks takes over top spot in FDA's center for biologics after four-year training period as deputy director; his background appears well suited to what promises to be a transformative era in medicine.

You may also be interested in...

Gene Editing: Off-Target Effects Should Be A Key Safety Focus During Development, US FDA Says

Clinical development programs for human gene therapy products that incorporate genome editing should address the potential risks of off-target editing as well as unintended consequences of on-target effects, agency says in new draft guidance.

CBER Reorganization Groups Hematology Products With Cell Therapies

Director Peter Marks makes his mark in shuffling of office divisions aimed at regulatory efficiency.

FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts